Shahini Najmeh, Talaei Ali, Shalbafan Mohammadreza, Faridhosseini Farhad, Ziaee Maliheh
Golestan Resaerch Center of Psychiatry, Golestan University of Medical Sciences, Gorgan, Iran.
Psychiatry and Behavioral Sciences Research Center, Ibn-e-Sina Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Basic Clin Neurosci. 2021 Jul-Aug;12(4):489-498. doi: 10.32598/bcn.2021.1998.1. Epub 2021 Jul 1.
Inflammatory processes in the brain play an important role in the etiopathogenesis of Obsessive-Compulsive Disorder (OCD). Cyclooxygenase inhibitors, such as celecoxib reduce the production of proinflammatory cytokines. This double-blind study aimed to investigate the effects of adding celecoxib to Selective Serotonin Reuptake Inhibitors (SSRIs)on treating OCD.
Sixty patients who met the diagnosis criteria for OCD based on the Diagnostic and Statistical Manual of Mental Disorders -Fourth Edition- Text Revision (DSM-IV-TR) were recruited in the present study. Two psychiatrists independently confirmed the diagnosis by performing structured interviews. The study participants included 23 patients who received SSRIs and celecoxib (400 mg twice daily) and 22 patients in the control group that received SSRIs and placebo. Moreover, at baseline, in weeks 4, 8, and 12, the explored patients were assessed by a psychiatrist using the Yale-Brown Obsessive-Compulsive Scale (Y-BCOS).
A significant difference was observed in the change of scores on the Y-BOCS in week 12, compared with the onset of the study between the study groups (t= -8.976, df=38, P=0.001). There was a significant difference between the study groups in obsession (F= 49.19, df= 1, P≤0.001), compulsion (F= 13.78, df= 1, P= 0.001), and OCD (F= 57.25, df= 1, P≤0.001), i.e., higher in the celecoxib group.
This study showed that adjuvant treatment with celecoxib can further improve the symptoms of OCD in individuals receiving SSRIs.
大脑中的炎症过程在强迫症（OCD）的病因发病机制中起重要作用。环氧化酶抑制剂，如塞来昔布，可减少促炎细胞因子的产生。这项双盲研究旨在探讨在选择性5-羟色胺再摄取抑制剂（SSRIs）基础上加用塞来昔布治疗强迫症的效果。
本研究招募了60名符合《精神疾病诊断与统计手册（第四版），修订版》（DSM-IV-TR）强迫症诊断标准的患者。两名精神科医生通过进行结构化访谈独立确认诊断。研究参与者包括23名接受SSRIs和塞来昔布（每日两次，每次400毫克）的患者以及22名接受SSRIs和安慰剂的对照组患者。此外，在基线、第4周、第8周和第12周，由一名精神科医生使用耶鲁-布朗强迫症量表（Y-BCOS）对研究对象进行评估。
与研究开始时相比，第别为（t=-8.976，自由度=38，P=0.001）。研究组在强迫观念（F=49.19，自由度=1，P≤0.001）、强迫行为（F=13.78，自由度=1，P=0.001）和强迫症（F=57.25，自由度=1，P≤0.001）方面存在显著差异，即塞来昔布组更高。
本研究表明，塞来昔布辅助治疗可进一步改善接受SSRIs治疗的个体的强迫症症状。 12周时Y-BOCS评分变化在研究组之间存在显著差异，t值分
